Compare JAZZ & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAZZ | HLI |
|---|---|---|
| Founded | 2003 | 1972 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.6B |
| IPO Year | 2007 | 2015 |
| Metric | JAZZ | HLI |
|---|---|---|
| Price | $194.31 | $150.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $216.92 | $194.29 |
| AVG Volume (30 Days) | ★ 734.6K | 585.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.58% |
| EPS Growth | N/A | ★ 41.61 |
| EPS | N/A | ★ 4.74 |
| Revenue | $1,618,693,000.00 | ★ $2,389,416,000.00 |
| Revenue This Year | $6.13 | $14.31 |
| Revenue Next Year | $7.75 | $12.52 |
| P/E Ratio | ★ N/A | $32.04 |
| Revenue Growth | N/A | ★ 24.81 |
| 52 Week Low | $98.96 | $134.41 |
| 52 Week High | $200.24 | $211.78 |
| Indicator | JAZZ | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 58.03 |
| Support Level | $159.78 | $135.21 |
| Resistance Level | $198.00 | $197.08 |
| Average True Range (ATR) | 4.75 | 4.03 |
| MACD | 0.67 | 2.34 |
| Stochastic Oscillator | 69.84 | 93.35 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.